Upstate Active Clinical Trials

Study Title:

A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis

What is the purpose of the study?

Compare 2 doses of fingolimod to copaxone and to evaluate the efficacy and safety of fingolimod for the treatment of patients with relapsing-remitting Multiple Sclerosis

Upstate Institutional Review Board (IRB) Number:

345511

Study Phase:

VI

Patient Age Group:

Adults

Principal Investigator:

Burk Jubelt, MD

What is involved if I participate?

  • How long is the study?
    12 Months
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    MRI, Neurological assessments and safety assessments.

Where will the study take place?

Institute for Human Performance

ClinicalTrials.Gov ID:

NCT01633112

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Andrea E McGlond
Phone: 315-464-6409
Email: mcglonda@upstate.edu

Return to Previous Page || Search Again